Cdipt Antibody

What is CDIPT and why is it an important research target?

CDIPT (CDP-Diacylglycerol--Inositol 3-Phosphatidyltransferase) is a critical enzyme that catalyzes the biosynthesis of phosphatidylinositol (PtdIns) and mediates PtdIns:inositol exchange reactions . This enzyme plays a fundamental role in reducing excessive cellular PtdIns content through its exchange activity, which is dependent on CMP tightly bound to the enzyme . As a multi-pass membrane protein localized to the endoplasmic reticulum membrane and cell membrane, CDIPT serves as an important research target for studies involving phospholipid metabolism, cell signaling pathways, and membrane biology . Research on CDIPT has implications for understanding various cellular processes and potential disease mechanisms related to phosphoinositide metabolism.

What types of CDIPT antibodies are available and how should I select one for my research?

Several types of CDIPT antibodies are available targeting different amino acid regions of the protein. The primary options include antibodies targeting the central region (amino acids 99-125) and those targeting amino acids 128-178 . When selecting an appropriate antibody, researchers should consider:

• Epitope specificity: Antibodies targeting AA 99-125 from the central region of human CDIPT are widely available and well-characterized .

• Host species: Most CDIPT antibodies are rabbit polyclonal, though some mouse monoclonal options exist .

• Reactivity profile: Different antibodies offer reactivity with human, mouse, and/or rat samples .

• Conjugation options: Available as unconjugated or conjugated to FITC, Biotin, APC, or PE depending on experimental requirements .

• Application compatibility: Select based on intended use for Western Blotting, Flow Cytometry, ELISA, or Immunohistochemistry .

The selection should align with your specific experimental design, target species, and detection method.

What are the optimal storage conditions for maintaining CDIPT antibody activity?

To maintain optimal CDIPT antibody activity, proper storage is crucial. Most CDIPT antibodies should be stored at -20°C for long-term preservation . For short-term storage (up to one week), temperatures between 2-8°C may be acceptable . Antibodies are typically formulated in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide to maintain stability . It is essential to avoid repeated freeze-thaw cycles, as these can significantly degrade antibody quality and reduce binding efficacy . Most manufacturers indicate that properly stored antibodies maintain activity for approximately 12 months from the date of shipment . For antibodies in liquid formulation, aliquoting upon receipt is recommended to minimize freeze-thaw cycles when only small volumes are needed for experiments.

What are the validated applications for CDIPT antibodies and their optimal working dilutions?

CDIPT antibodies have been validated for multiple experimental applications with specific optimal working dilutions:

When optimizing protocols, it is advisable to begin with the manufacturer's recommended dilution range and adjust based on signal intensity and background levels in your specific experimental system . Validation data shows successful detection of CDIPT in mouse stomach tissue lysates via Western blot and in human brain tissue via immunohistochemistry .

How should I design an effective Western blot protocol for CDIPT detection?

Designing an effective Western blot protocol for CDIPT detection requires careful consideration of several factors:

• Sample preparation:

  • Extract proteins from cells/tissues using RIPA buffer with protease inhibitors

  • Load 25-35 μg of total protein per lane (as validated in mouse stomach tissue lysates)

• Electrophoresis and transfer:

  • Use 12-15% SDS-PAGE gels (CDIPT is approximately 21 kDa)

  • Transfer to PVDF membranes at 100V for 60-90 minutes in cold transfer buffer

• Blocking and antibody incubation:

  • Block with 5% non-fat milk in TBST for 1 hour at room temperature

  • Incubate with primary CDIPT antibody (1:500-2000 dilution) overnight at 4°C

  • Wash 3-5 times with TBST, 5 minutes each

  • Incubate with HRP-conjugated secondary antibody (1:5000-10000) for 1 hour at room temperature

• Detection:

  • Develop using ECL substrate

  • Expected band size is approximately 21 kDa for human CDIPT

For troubleshooting weak signals, consider extending primary antibody incubation time, reducing antibody dilution, or using enhanced sensitivity detection systems . Non-specific bands may be reduced by increasing blocking time or adjusting antibody dilutions.

What controls should be included when using CDIPT antibodies in immunohistochemistry?

When conducting immunohistochemistry experiments with CDIPT antibodies, proper controls are essential for result validation:

• Positive tissue controls:

  • Human brain tissue has been validated for CDIPT expression

  • Mouse stomach tissue also shows detectable expression levels

• Negative controls:

  • Primary antibody omission control: Replace primary antibody with antibody diluent

  • Isotype control: Use non-specific rabbit IgG at the same concentration as the CDIPT antibody

  • Blocking peptide control: Pre-incubate antibody with the immunizing peptide (AA 99-125 or 128-178) to confirm specificity

• Technical controls:

  • Endogenous peroxidase blocking control

  • Antigen retrieval optimization (typically heat-induced epitope retrieval in citrate buffer pH 6.0)

  • Titration series to optimize antibody concentration (start with 1:100-500 dilution)

Documented validation of formalin-fixed and paraffin-embedded human brain tissue with DAB staining demonstrates specific CDIPT detection, providing a benchmark for expected staining patterns .

How can I distinguish between specific and non-specific binding when using CDIPT antibodies?

Distinguishing between specific and non-specific binding is a critical aspect of antibody-based research. For CDIPT antibodies, researchers should implement multiple validation strategies:

• Epitope blocking experiments:

  • Pre-incubate the antibody with excess immunizing peptide (from AA 99-125 or 128-178 regions)

  • Compare staining patterns between blocked and unblocked antibody samples

  • Specific binding should be significantly reduced in blocked samples

• Multiple antibody validation:

  • Use antibodies targeting different epitopes of CDIPT (e.g., compare results from antibodies targeting AA 99-125 versus AA 128-178)

  • Consistent detection patterns across different antibodies suggest specific binding

• Knockdown/knockout validation:

  • Compare antibody reactivity in wildtype versus CDIPT-silenced or knockout samples

  • Significant reduction in signal in knockout samples confirms specificity

• Cross-reactivity assessment:

  • Test antibody reactivity in species not listed in the reactivity profile

  • Unexpected strong signals may indicate cross-reactivity with other proteins

What are the key considerations for multiplexed immunofluorescence studies involving CDIPT?

Multiplexed immunofluorescence studies involving CDIPT require careful planning to achieve reliable co-localization data:

• Antibody selection factors:

  • Choose conjugated CDIPT antibodies (FITC, PE, APC) for direct detection

  • Ensure spectral compatibility with other fluorophores in your panel

  • Consider using different host species for co-staining antibodies to avoid cross-reactivity

• Sequential staining protocol recommendations:

  • Begin with lowest concentration antibody and progress to higher concentration

  • Include adequate washing steps between antibody applications

  • Consider using tyramide signal amplification for weak CDIPT signals

• Optimizing for cellular localization studies:

  • CDIPT localizes to endoplasmic reticulum membrane and cell membrane

  • Pair with established ER markers (e.g., calnexin, PDI) for co-localization studies

  • Super-resolution microscopy may be required to distinguish between closely associated membrane structures

• Flow cytometry considerations:

  • MCF-7 cells have been validated for CDIPT detection by flow cytometry

  • Use APC-conjugated antibodies (ABIN1964161) for red channel detection to avoid autofluorescence in the green spectrum

  • Compare to negative control cells as baseline (as demonstrated in validated flow cytometry histograms)

Spectral overlap and compensation requirements should be carefully addressed when designing panels including CDIPT antibodies conjugated to fluorophores.

How can I troubleshoot inconsistent results between different lots of CDIPT antibodies?

Antibody lot-to-lot variability can significantly impact experimental reproducibility. When encountering inconsistencies with different lots of CDIPT antibodies:

• Comparative validation approaches:

  • Perform side-by-side testing of old and new antibody lots

  • Create standard curves with recombinant CDIPT protein to quantify binding affinities

  • Document staining patterns across multiple applications to identify specific changes

• Antibody characterization methods:

  • Measure protein concentration to confirm manufacturer specifications

  • Assess purity through SDS-PAGE analysis

  • Evaluate aggregation status by dynamic light scattering

• Critical variables to standardize:

  • Storage conditions (maintain consistent aliquoting practices)

  • Incubation times and temperatures

  • Sample preparation methods

  • Detection systems and exposure settings

• Mitigation strategies:

  • Secure sufficient quantities of a well-performing lot for critical studies

  • Consider switching to monoclonal antibodies which typically show less lot-to-lot variation

  • Implement bridging studies when transitioning between lots

  • Create internal reference standards to normalize between experiments

Documenting detailed protocols and experimental conditions can help identify the source of variability when inconsistencies arise between antibody lots.

What approaches can be used to study CDIPT phosphatidylinositol synthase activity in conjunction with antibody-based detection?

Studying CDIPT enzymatic activity alongside antibody-based detection provides complementary insights into both protein presence and function:

• Combined enzymatic-immunological assays:

  • Measure phosphatidylinositol synthase activity using radiolabeled substrates

  • Correlate activity levels with protein expression detected via immunoblotting

  • Fractionate cellular compartments to determine relationship between localization and activity

• Activity-based protein profiling:

  • Use activity-based probes that bind to active CDIPT

  • Couple with immunoprecipitation using anti-CDIPT antibodies

  • Analyze active versus total CDIPT pools

• Structure-function relationship studies:

  • Generate mutations in key functional domains

  • Use antibodies targeting different epitopes (AA 99-125 versus 128-178) to detect potential conformational changes

  • Correlate structural alterations with changes in enzymatic activity

• In situ activity visualization:

  • Combine fluorescently-tagged PtdIns reporters with immunofluorescence

  • Use APC-conjugated CDIPT antibodies for compatible fluorescence channels

  • Perform live-cell imaging followed by fixation and antibody staining

Remember that CDIPT may exist in different functional states depending on CMP binding and membrane environment, which can affect both antibody accessibility and enzymatic activity .

How can CDIPT antibodies be utilized in studying membrane biology and lipid metabolism pathways?

CDIPT antibodies serve as valuable tools for investigating the intersection of membrane biology and lipid metabolism:

• Membrane subdomain localization studies:

  • Use detergent resistance fractionation to isolate membrane microdomains

  • Apply CDIPT antibodies to identify distribution across membrane fractions

  • Combine with markers of lipid rafts, caveolae, and other specialized membrane domains

• Stress response monitoring:

  • Track CDIPT localization changes during ER stress using immunofluorescence

  • Quantify expression level changes via Western blotting during lipid perturbations

  • Apply flow cytometry with conjugated antibodies to measure cell-population responses

• Interaction network mapping:

  • Perform co-immunoprecipitation with CDIPT antibodies to identify protein partners

  • Use proximity ligation assays to confirm in situ interactions

  • Combine with lipidomic analyses to correlate with phosphoinositide profiles

• Disease model applications:

  • Compare CDIPT distribution in normal versus pathological tissues via IHC

  • Validate expression changes in disease models using quantitative immunoblotting

  • Assess post-translational modifications using modification-specific antibodies in conjunction with general CDIPT detection

The dual localization of CDIPT to endoplasmic reticulum and cell membranes makes it particularly valuable for studying membrane biogenesis and phospholipid transport between organelles .

What are the considerations for using CDIPT antibodies in developmental and tissue-specific expression studies?

When employing CDIPT antibodies for developmental and tissue-specific expression analyses, researchers should address several important considerations:

• Developmental stage-specific protocols:

  • Adjust fixation conditions based on tissue density and developmental stage

  • Optimize antigen retrieval methods for embryonic versus adult tissues

  • Consider whole-mount immunostaining for embryonic samples with appropriate permeabilization

• Tissue cross-reactivity profile:

  • Validated reactivity in human brain tissue via IHC and mouse stomach tissue via Western blot

  • Predicted reactivity in rat tissues requires validation

  • Create tissue microarrays to systematically profile expression across multiple tissues

• Spatial expression analysis methods:

  • Combine with laser capture microdissection for region-specific analysis

  • Use multiplexed IHC to correlate with cell-type specific markers

  • Consider RNAscope® paired with immunofluorescence to correlate mRNA and protein expression

• Quantitative comparison approaches:

  • Develop standardized staining and imaging protocols for cross-tissue comparison

  • Use digital pathology tools for objective quantification of staining intensity

  • Implement normalization strategies when comparing expression across diverse tissues

For developmental studies, remember that membrane composition and cellular architecture change significantly during development, potentially affecting epitope accessibility and antibody binding characteristics.

How might CDIPT antibodies contribute to emerging research in phosphoinositide-related disorders?

CDIPT antibodies hold significant potential for advancing research in phosphoinositide-related disorders through several promising approaches:

• Biomarker development opportunities:

  • Assess CDIPT expression alterations in patient samples via immunohistochemistry

  • Evaluate CDIPT activity-to-expression ratios as potential diagnostic indicators

  • Develop high-throughput screening methods using CDIPT antibodies for patient stratification

• Mechanistic investigation approaches:

  • Use immunofluorescence to track CDIPT redistribution in disease models

  • Apply proximity ligation assays to identify altered protein interactions in pathological states

  • Combine with phosphoinositide sensors to correlate enzymatic activity with lipid distribution

• Therapeutic monitoring applications:

  • Evaluate changes in CDIPT expression and localization during experimental treatments

  • Use flow cytometry with conjugated antibodies to assess population responses to therapy

  • Develop antibody-based assays for measuring pharmacodynamic responses in clinical samples

• Genetic disorder models:

  • Characterize CDIPT expression in rare genetic disorders affecting phosphoinositide metabolism

  • Compare knockin/knockout models using antibody-based detection methods

  • Evaluate tissue-specific consequences of CDIPT mutations using immunohistochemistry

As phosphoinositide metabolism becomes increasingly recognized in neurological, metabolic, and developmental disorders, CDIPT antibodies will serve as key tools for dissecting pathological mechanisms and therapeutic responses.

What methodological advances are needed to improve CDIPT antibody specificity and sensitivity in research applications?

Despite current availability of CDIPT antibodies, several methodological advances could significantly enhance their utility in research:

• Next-generation antibody development needs:

  • Single-domain antibodies (nanobodies) for improved access to membrane-embedded epitopes

  • Conformation-specific antibodies to distinguish active versus inactive CDIPT states

  • Phosphorylation-state specific antibodies to detect regulatory modifications

• Validation strategy enhancements:

  • Implementation of CRISPR/Cas9 knockout validation across multiple cell lines

  • Development of standardized positive and negative control lysates/tissues

  • Creation of epitope-tagged CDIPT reference standards for absolute quantification

• Application-specific optimization approaches:

  • Improved permeabilization methods for membrane protein detection in fixed cells

  • Sample preparation techniques that preserve native membrane architecture

  • Specialized fixatives for retention of phospholipid-protein complexes during immunostaining

• Reproducibility enhancement tools:

  • Recombinant antibody production to eliminate animal-to-animal variation

  • Machine learning algorithms for automated antibody validation and quality control

  • Open-source protocol repositories specific to membrane protein detection

The continued refinement of antibody technology will be particularly valuable for studying CDIPT, as its membrane localization and association with lipid environments present unique challenges for consistent and specific detection .